Seoul, South Korea

Dong Keun Han

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 205(Granted Patents)


Company Filing History:


Years Active: 1993-2022

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents

Title: Innovations of Dong Keun Han

Introduction

Dong Keun Han is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antitumor effects. With a total of 17 patents to his name, his work has the potential to impact cancer treatment and prevention.

Latest Patents

One of Dong Keun Han's latest patents is an imidazooxazole derivative that exhibits antitumor effects. This pharmaceutical composition is designed for preventing and treating tumors. It includes an imidazooxazole derivative compound, a solvate, a stereoisomer, or a pharmaceutically acceptable salt as an active ingredient. The composition is administered to individuals who have developed a tumor or are at risk of developing one, thereby providing a means to prevent or treat tumors effectively.

Career Highlights

Throughout his career, Dong Keun Han has worked with notable organizations such as the Korea Institute of Science and Technology and Dentkist, Inc. His experience in these institutions has allowed him to refine his research and contribute to advancements in pharmaceutical sciences.

Collaborations

Dong Keun Han has collaborated with several professionals in his field, including Kwideok Park and Jae-Jin Kim. These collaborations have likely enhanced the quality and scope of his research endeavors.

Conclusion

Dong Keun Han's innovative work in developing pharmaceutical compositions for tumor prevention and treatment showcases his dedication to advancing medical science. His contributions are significant in the ongoing fight against cancer, and his patents reflect a commitment to improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…